Skip to content

BR1015-2

DRUG11 trials

Sponsors

Boryung Pharmaceutical Co., Ltd

Conditions

Essential HypertensionHypertension

Phase 1

A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between BR1015-1 and BR1015-2 in Healthy Volunteers
CompletedNCT05097794
Boryung Pharmaceutical Co., LtdHypertension
Start: 2021-08-16End: 2021-10-22Updated: 2021-11-22
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions in Healthy Volunteers
CompletedNCT06008015
Boryung Pharmaceutical Co., LtdHypertension
Start: 2023-09-04End: 2023-10-03Updated: 2023-10-31
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions in Healthy Volunteers
CompletedNCT06008028
Boryung Pharmaceutical Co., LtdHypertension
Start: 2023-08-10End: 2023-10-06Updated: 2023-11-18
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed Conditions
CompletedNCT06744062
Boryung Pharmaceutical Co., LtdEssential Hypertension
Start: 2025-01-05End: 2025-03-19Updated: 2025-04-09
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions
CompletedNCT06744127
Boryung Pharmaceutical Co., LtdEssential Hypertension
Start: 2025-01-03End: 2025-03-14Updated: 2025-04-09
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
CompletedNCT06744439
Boryung Pharmaceutical Co., LtdEssential Hypertension
Start: 2025-01-09End: 2025-03-16Updated: 2025-04-09
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions
CompletedNCT06744426
Boryung Pharmaceutical Co., LtdEssential Hypertension
Start: 2025-01-04End: 2025-03-12Updated: 2025-04-09
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions
Not yet recruitingNCT07421388
Boryung Pharmaceutical Co., LtdEssential Hypertension
Start: 2026-04-09End: 2026-06-07Target: 48Updated: 2026-02-19
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
Not yet recruitingNCT07421414
Boryung Pharmaceutical Co., LtdEssential Hypertension
Start: 2026-04-19End: 2026-06-17Target: 48Updated: 2026-02-19
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions
Not yet recruitingNCT07421375
Boryung Pharmaceutical Co., LtdEssential Hypertension
Start: 2026-04-02End: 2026-05-31Target: 58Updated: 2026-02-19
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions
Not yet recruitingNCT07421401
Boryung Pharmaceutical Co., LtdEssential Hypertension
Start: 2026-04-13End: 2026-06-11Target: 58Updated: 2026-02-19